Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

Subscribe Publication Updates

Publication Updates

10 Apr
AHFS Drug Information April 2018 update

This update contains 5 new monographs, 20 revised monographs and changes to MedWatch alerts for 3 monographs.

New monographs: ARIPiprazole Tablets with Sensor; Angiotensin II; Lutetium Lu 177 Dotatate; Tezacaftor and Ivacaftor; Apalutamide.

Revised monographs: Copyrights; Editorial Staff; Candesartan; Olmesartan; Gefitinib; Sofosbuvir; Albiglutide; Dulaglutide; Selexipag; Obeticholic Acid; Insulin Degludec;

Deoxycholic Acid; Avelumab; Loperamide; Corticosteroids General Statement; Ketorolac; Clarithromycin; Losartan; buPROPion; Irbesartan.

MedWatch Alerts: Loperamide; Clarithromycin; Obeticholic Acid.

10 Apr
Stockley’s Herbal Medicines Interactions April 2018 update

Papaya has been added; Coptis has been revised.

New monographs: Papaya

Revised monographs: Coptis

Minor updates: European Pharmacopoeia information globally updated.

10 Apr
Herbal Medicines April 2018 update

Chinese Goldthread and Papaya have been added for this update. Raspberry, Rhubarb and Red clover have been selectively revised. Pharmacopoeial information and Appendix 2 have been updated.

New monographs: Chinese Goldthread, Papaya

Selective revisions: Raspberry, Rhubarb, Red clover

Minor updates: European Pharmacopoeia has been globally updated; Appendix 2 have also been updated.

 

10 Apr
Stockley’s Interaction Alerts April 2018 Update

New and updated Alerts now available

For April, 945 new Alerts have been added, and 178 existing Alerts have been updated.

 

 

10 Apr
BNFC April 2018 update

This update contains 3 significant changes and 3 dose changes.

Significant Changes:

  • Malaria, prophylaxis: update to country recommendations and guidance.
  • Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients [MHRA/CHM advice].
  • Sinusitis (acute): updated guidance.

Dose Changes:

  • Hydroxycarbamide.
  • Lacosamide.
  • Papaveretum [clarification of dosing].

For further details on changes in the BNFC click on changes

10 Apr
BNF April 2018 update

This update contains 10 significant changes, 3 new preparations and 4 dose changes. 

Significant Changes:

  • Ceritinib for untreated ALK-positive non-small-cell lung cancer [NICE guidance].
  • Daclizumab (Zinbryta®) suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy [MHRA/CHM advice].
  • Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer [NICE guidance].
  • Glecaprevir with pibrentasvir for treating chronic hepatitis C [NICE guidance].
  • Golimumab for treating non-radiographic axial spondyloarthritis [NICE guidance].
  • Ibrutinib for treating relapsed or refractory mantle cell lymphoma [NICE guidance].
  • Lenvatinib with everolimus for previously treated advanced renal cell carcinoma [NICE guidance].
  • Malaria, prophylaxis: update to country recommendations and guidance.
  • Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients [MHRA/CHM advice].
  • Sinusitis (acute): updated guidance.

Dose Changes:

  • Alprostadil [Initial dose for erectile dysfunction and neurogenic erectile dysfunction for Viridal® Duo].
  • Hydroxycarbamide.
  • Lacosamide.
  • Papaveretum [clarification of dosing].

New Preparations: Fotivda® [tivozanib], Ocrevus ® [ocrelizumab], Plenvu® [Macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride]

For further details on changes in the BNF click on changes

View more